A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD)

The PI of this project was:

This project was funded by: Merck

The term of this project was: April 2015 to January 2018

The number of subjects scanned during this project was: 20